We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Uncovering the Pathology of a Rare Pediatric Leukemia

Uncovering the Pathology of a Rare Pediatric Leukemia

Uncovering the Pathology of a Rare Pediatric Leukemia

Uncovering the Pathology of a Rare Pediatric Leukemia

Credit: Northwestern Medicine
Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Uncovering the Pathology of a Rare Pediatric Leukemia"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A team of scientists has demonstrated the mechanism by which ETO2-GLIS2, a gene fusion, promotes the development of an aggressive form of pediatric leukemia. The findings, published in Cancer Cell, also reveal an opportunity for the development of therapeutics.

The study was co-authored by John Crispino, PhD, the Robert I. Lurie, MD, and Lora S. Lurie Professor of Medicine in the Division of Hematology and Oncology.

Acute megakaryoblastic leukemia (AMKL), a rare type of blood cancer predominantly found in children, has two major pediatric subgroups: AMKL in patients with Down syndrome and those without. While the disease in those with Down syndrome (DS) is relatively well-defined and carries a good prognosis, non-DS AMKL is much less well-understood.

Recently, scientists discovered that a gene fusion called ETO2-GLIS2 — produced by an inversion on chromosome 16 — is present in 20 to 30 percent of cases of non-DS AMKL, and is associated with a very poor patient prognosis. But up until now, it was unclear exactly how this gene fusion blocks normal cell differentiation, a hallmark of leukemia.

In the current study, the scientists illustrated how ETO2-GLIS2 induces an irregular transcription network that underlies AMKL. They further demonstrated that expression of a peptide that inhibits ETO2-GLIS2 oligomerization could release the differentiation block — insights which could inform the development of novel therapeutics.

“Acute megakaryoblastic leukemia is a devastating blood cancer that requires new targeted and efficacious therapies,” Crispino said. “The discovery of the mechanism by which ETO2-GLIS2 fusion promotes leukemia provides important new insights into ways to target these malignant cells.”

This article has been republished from materials provided by Northwestern Medicine. Note: material may have been edited for length and content. For further information, please contact the cited source.


Thirant, C., Ignacimouttou, C., Lopez, C. K., Diop, M., Mouël, L. L., Thiollier, C., . . . Mercher, T. (2017). ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell, 31(3), 452-465. doi:10.1016/j.ccell.2017.02.006